Gilead Sciences has completed its $21 billion acquisition of Immunomedics.
Back in September, Gilead and Immunomedics announced that Gilead, Immunomedics and Maui Merger Sub – a wholly owned subsidiary of Gilead – had signed a definitive merger agreement.
Immunomedics has now become a wholly owned subsidiary of Gilead.
“We are very pleased to reach today’s milestone and to welcome the talented Immunomedics team to the Gilead family. There is a lot of important work ahead of us to deliver on the vast potential that Trodelvy offers for patients with cancer,” said Daniel O’Day, Chairman and CEO of Gilead Sciences.
“Together we will bring Trodelvy to many more patients around the world with triple-negative breast cancer and continue to explore its potential in many other types of cancer, both as a monotherapy and in combination with other treatments.”